Hypnotic Medication and Cardiovascular Risk in Insomnia Patients

Overview

This study investigated the cardiovascular risks associated with hypnotic use in individuals with insomnia using UK Biobank data. Benzodiazepine use was linked to increased risks of coronary heart disease, heart failure, and cardiovascular mortality, whereas Z-drugs showed no significant cardiovascular hazards.

Background

Cardiovascular diseases (CVDs) remain a leading global health challenge, with sleep disturbances increasingly recognized as contributing risk factors. Insomnia management often involves hypnotic agents, primarily benzodiazepines and Z-drugs (Z-meds), which are widely prescribed but raise concerns about safety and dependency. Prior research suggested some hypnotics might worsen cardiovascular outcomes in specific populations, but their effects in the general insomnia population have been unclear. This study aimed to clarify these associations using a large prospective cohort and genetic analyses.

Data Highlights

Key Findings

• Benzodiazepine use was significantly associated with increased risk of coronary heart disease, heart failure, and cardiovascular mortality in insomnia patients.
• No significant association was found between Z-drugs (Z-meds) and coronary heart disease, stroke, or cardiovascular mortality.
• Sensitivity analyses including inverse probability of treatment weighting, competing risk models, and shared frailty models confirmed the robustness of these associations.
• Drug-target Mendelian randomization analyses supported the cardiovascular safety of Z-drugs in the general population.
• The study highlights heterogeneous cardiovascular risk profiles among different hypnotic categories in insomnia sufferers.

Clinical Implications

Clinicians should exercise caution when prescribing benzodiazepines to patients with insomnia due to their association with increased cardiovascular risks. Z-drugs may represent a safer alternative regarding cardiovascular outcomes, but clinical decisions should also consider other safety and dependency factors. These findings underscore the importance of individualized treatment strategies and monitoring cardiovascular health in insomnia management.

Conclusion

This comprehensive analysis combining observational and genetic data reveals that benzodiazepines, but not Z-drugs, are linked to elevated cardiovascular risk in insomnia patients. These results inform safer hypnotic prescribing practices to mitigate cardiovascular complications.

References

1. Guettler NJ 2022 -- Different associations with incident cardiovascular events between different categories of hypnotics in insomnia patients